Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 274

1.

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI; RESULT Study Group.

Diabetes Obes Metab. 2006 Jan;8(1):49-57.

PMID:
16367882
[PubMed - indexed for MEDLINE]
4.

Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes.

Rosenstock J, Chou HS, Matthaei S, Seidel DK, Hamann A.

Diabetes Obes Metab. 2008 Sep;10(10):862-73. doi: 10.1111/j.1463-1326.2007.00815.x. Epub 2008 Jan 14.

PMID:
18201206
[PubMed - indexed for MEDLINE]
5.

Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.

Rosenstock J, Rood J, Cobitz A, Biswas N, Chou H, Garber A.

Diabetes Obes Metab. 2006 Nov;8(6):650-60.

PMID:
17026489
[PubMed - indexed for MEDLINE]
6.

Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone.

Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M.

Exp Clin Endocrinol Diabetes. 2008 Jan;116(1):6-13. Epub 2007 Dec 20.

PMID:
18095238
[PubMed - indexed for MEDLINE]
7.

Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.

Chou HS, Palmer JP, Jones AR, Waterhouse B, Ferreira-Cornwell C, Krebs J, Goldstein BJ.

Diabetes Obes Metab. 2008 Aug;10(8):626-37. Epub 2007 Jul 21.

PMID:
17645558
[PubMed - indexed for MEDLINE]
8.

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.

Clin Ther. 2005 Oct;27(10):1548-61.

PMID:
16330291
[PubMed - indexed for MEDLINE]
9.

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN.

Diabet Med. 2000 Jan;17(1):40-7.

PMID:
10691158
[PubMed - indexed for MEDLINE]
10.

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea.

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjörnsdottir S, Camisasca RP, Couturier A, Baron MA.

Diabetes Obes Metab. 2008 Nov;10(11):1047-56. doi: 10.1111/j.1463-1326.2008.00859.x. Epub 2008 Feb 18.

PMID:
18284434
[PubMed - indexed for MEDLINE]
11.
12.

The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.

Rajagopalan R, Xu Y, Abbadessa M; Quartet Study Group.

Am J Geriatr Pharmacother. 2006 Jun;4(2):123-33.

PMID:
16860259
[PubMed - indexed for MEDLINE]
13.

Combination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitus.

Kerenyi Z, Samer H, James R, Yan Y, Stewart M.

Diabetes Res Clin Pract. 2004 Mar;63(3):213-23.

PMID:
14757293
[PubMed - indexed for MEDLINE]
14.

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.

PMID:
15978304
[PubMed - indexed for MEDLINE]
15.
16.

Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control.

Rosenstock J, Rood J, Cobitz A, Huang C, Garber A.

Diabetes Obes Metab. 2006 Nov;8(6):643-9.

PMID:
17026488
[PubMed - indexed for MEDLINE]
18.

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.

Diabetes Obes Metab. 2007 Mar;9(2):166-74.

PMID:
17300592
[PubMed - indexed for MEDLINE]
19.

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.

PMID:
16882108
[PubMed - indexed for MEDLINE]
20.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk